Edition:
United States

Sangamo Therapeutics Inc (SGMO.OQ)

SGMO.OQ on NASDAQ Stock Exchange Global Select Market

16.40USD
14 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$16.40
Open
--
Day's High
--
Day's Low
--
Volume
100
Avg. Vol
359,311
52-wk High
$18.40
52-wk Low
$2.85

Latest Key Developments (Source: Significant Developments)

Sangamo Says European Medicines Agency Recommends Orphan Medicinal Product Designation For Investigational Genome Editing Treatments
Thursday, 7 Dec 2017 04:22pm EST 

Dec 7 (Reuters) - Sangamo Therapeutics Inc ::SANGAMO ANNOUNCES EUROPEAN MEDICINES AGENCY RECOMMENDATION OF ORPHAN MEDICINAL PRODUCT DESIGNATION FOR INVESTIGATIONAL GENOME EDITING TREATMENTS FOR MPS I AND MPS II.SANGAMO THERAPEUTICS - PHASE 1/2 CLINICAL TRIALS FOR PROGRAMS, EVALUATING SB-318 & SB-913 IN ADULTS WITH MPS I AND MPS II, ARE ENROLLING SUBJECTS.  Full Article

Sangamo says patient received therapy intended to precisely edit DNA of cells directly inside body​
Wednesday, 15 Nov 2017 01:10am EST 

Nov 15 (Reuters) - Sangamo Therapeutics Inc -:Sangamo announces treatment of first patient in landmark phase 1/2 clinical trial evaluating in vivo genome editing for MPS II.‍A patient has received a therapy intended to precisely edit DNA of cells directly inside body​.  Full Article

Sangamo Therapeutics posts Q3 loss per share $0.15
Thursday, 9 Nov 2017 04:01pm EST 

Nov 9 (Reuters) - Sangamo Therapeutics Inc :Sangamo Therapeutics reports third quarter 2017 financial results.Q3 revenue $11.8 million versus I/B/E/S view $10.4 million.Q3 loss per share $0.15.Sees FY 2017 revenue $30 million to $40 million.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Sangamo Therapeutics Inc - ‍company expects that revenues will be in range of $30 million to $40 million in 2017​.FY2017 revenue view $33.2 million -- Thomson Reuters I/B/E/S.  Full Article

Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400
Monday, 2 Oct 2017 07:30am EDT 

Oct 2 (Reuters) - Bioverativ Inc :Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400 -- a gene-edited cell therapy candidate -- to treat beta-thalassemia.Sangamo Therapeutics Inc - ‍expects to open several clinical sites across United States and begin enrolling patients in first half of 2018​.Sangamo Therapeutics - based on deal terms, Sangamo responsible for conducting ST-400 phase 1/2 clinical trial.Sangamo Therapeutics - based on deal terms, Bioverativ responsible for subsequent worldwide clinical development, manufacturing, commercialization.  Full Article

Pfizer and Sangamo updates on early stage trial on its blood disorder therapy
Friday, 25 Aug 2017 08:00am EDT 

Aug 25 (Reuters) - Pfizer Inc ::Sangamo and Pfizer announce first patient receives treatment in Phase 1/2 clinical trial evaluating SB-525 investigational gene therapy for Hemophilia A.  Full Article

Sangamo Therapeutics reports Q2 loss per share $0.17
Wednesday, 9 Aug 2017 04:01pm EDT 

Aug 10 (Reuters) - Sangamo Therapeutics Inc -:Sangamo Therapeutics reports second quarter 2017 financial results.Q2 revenue $8.3 million versus $3.7 million.Q2 loss per share $0.17.Sees FY 2017 revenue $30 million to $40 million.Q2 revenue view $6 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Sangamo Therapeutics Inc - Sangamo expects that operating expenses will be in range of $90 million to $100 million for 2017.Sangamo Therapeutics Inc - Sangamo expects that its cash, cash equivalents and marketable securities will be at least $220 million at end of 2017.Q2 earnings per share view $-0.19, revenue view $6.0 million -- Thomson Reuters I/B/E/S.  Full Article

Sangamo receives fast track status from the FDA for SB-318 and SB-913
Thursday, 13 Jul 2017 04:01pm EDT 

July 13 (Reuters) - Sangamo Therapeutics Inc :Sangamo receives fast track designation from the FDA for SB-318 and SB-913 in vivo genome editing product candidates for the treatment of MPS I and MPS II.  Full Article

Sangamo announces pricing of $72.5 mln public offering of common stock
Wednesday, 21 Jun 2017 08:26am EDT 

June 21 (Reuters) - Sangamo Therapeutics Inc :Sangamo therapeutics announces pricing of $72.5 million public offering of common stock.Sangamo therapeutics announces pricing of $72.5 million public offering of common stock.Says public offering of 10.0 million common shares priced at $7.25per share.  Full Article

Sangamo Therapeutics announces proposed public offering of common stock
Tuesday, 20 Jun 2017 04:01pm EDT 

June 20 (Reuters) - Sangamo Therapeutics Inc -:Sangamo Therapeutics announces proposed public offering of common stock.  Full Article

Sangamo Therapeutics updates on SB-525 investigational hemophilia A gene therapy
Wednesday, 7 Jun 2017 07:30am EDT 

June 7 (Reuters) - Sangamo Therapeutics::Sangamo Therapeutics and Pfizer announce that SB-525 investigational hemophilia A gene therapy receives orphan medicinal product designation from the European medicines agency.Cos also announce Phase 1/2 clinical trial evaluating SB-525 in adults with severe hemophilia A is now open for enrollment.Sangamo Therapeutics Inc - initial data from study of SB-525 in adults with hemophilia A expected in late 2017 or early 2018.  Full Article

BRIEF-Sangamo Therapeutics posts Q3 loss per share $0.15

* Sangamo Therapeutics reports third quarter 2017 financial results